pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,955 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1027Endpoints780BioPharma Dive298BioSpace216Fierce Biotech205onclive165raps78globenewswire health
therapy area
allOncology6060Rare Disease1446Cardiology1094Hematology1026Immunology1004Vaccines906Pulmonology
  • Sanofi’s tolebrutinib gets CHMP backing for certain MS patients despite FDA rejection
    Sanofi’s tolebrutinib is on track to get an approval in Europe for a type of multiple sclerosis even after receiving a complete response letter from the FDA in December. On Friday, the European Med…
    Endpoints · 3mo ago↗ source
  • Pfizer’s strategy chief Andrew Baum steps down; Helus Pharma swaps out CEO after two months
    → Ex-Citi analyst Andrew Baum has left his role as chief strategy and innovation officer at Pfizer, but he will be a senior strategic advisor to CEO Albert Bourla. BMO Capital Markets broke the new…
    Endpoints · 3mo ago↗ source
  • Daiichi Sankyo postpones annual results, stock dips
    Daiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers. The Japanese company had intended to unveil its financials for its fiscal year…
← prev
page 78 of 79
next →
73
fda recalls47
fda medwatch38
fda press28
905
Psychiatry & CNS722
Ophthalmology421
Endocrinology & Metabolism382
Pain376
Infectious Disease356
Endpoints · 3mo ago↗ source
  • Opinion: I started medical school at 69 and will begin residency at 72. Here’s what I learned
    Starting residency at 72 isn’t for the faint of heart. But that’s what Dawn Zuidegeest-Craft is doing.
    STAT · 3mo ago↗ source
  • Psychedelics get a boost from the White House
    In this week’s STATus Report, host Alex Hogan chats with STAT Washington correspondent Daniel Payne about Trump's psychedelics EO.
    STAT · 3mo ago↗ source
  • Opinion: The local news crisis is also a public health crisis
    Health and science reporting is often treated as optional coverage. It is anything but.
    STAT · 3mo ago↗ source
  • Growing use of guest editors has turned some journals into a ‘playground of bad science’
    The problematic use of guest editors was spotlighted last week when a genetics journal retracted nearly an entire special issue.
    STAT · 3mo ago↗ source
  • A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
    This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.
    STAT · 3mo ago↗ source
  • STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
    A deal with Regeneron was the last of 17 initially sought by the White House.
    STAT · 3mo ago↗ source
  • FDA approves Regeneron's hearing loss gene therapy Otarmeni
    Regeneron has won the first-ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans to offer the treatment for free in the US, though that ...
    Endpoints · 3mo ago↗ source
  • Substance use disorder biotech Tempero to close after earlier 'serious' safety event
    Tempero Bio, a drug developer that had big ambitions to shake up the treatment of substance use disorders, is winding down operations, Endpoints News has learned. The shutdown comes after a "seriou…
    Endpoints · 3mo ago↗ source
  • Heart’s beat may help it beat cancer, mouse research suggests
    The constant pressure that the heart is under from beating thousands of times a day may create an environment hostile to cancers
    STAT · 3mo ago↗ source
  • STAT+: Trump’s boosting of psychedelics, cannabis signal a new era in GOP drug policy
    The Trump administration, in a stark departure from the "Just Say No" era, is funding psychedelics research and rescheduling marijuana.
    STAT · 3mo ago↗ source
  • Post-Hoc Live: MAHA, the new Trump CDC pick and RFK's vaccine agenda
    MAHA’s sway over HHS could face a fresh test now that President Trump has a new pick for CDC director: Erica Schwartz, a former deputy surgeon general. The position has been empty ...
    Endpoints · 3mo ago↗ source
  • Novartis' radioligand therapy Lutathera could soon face generic competition
    The radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring the ...
    Endpoints · 3mo ago↗ source
  • STAT+: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards
    Legislators in two states are resisting efforts to restrict prescription drug affordability boards.
    STAT · 3mo ago↗ source
  • Opinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk
    Since the 1918 pandemic, the military has acknowledged the threat of influenza. Now that’s changing.
    STAT · 3mo ago↗ source
  • STAT+: Sanofi research priorities in flux as new CEO logs in
    A gene therapy for deafness, all eyes on Erasca, and other biotech news from The Readout
    STAT · 3mo ago↗ source
  • David Reese to retire from Amgen
    Longtime Amgen leader David Reese is retiring at the end of June, Amgen announced Wednesday evening. Reese, 63, currently serves as chief technology officer, a role he created at Amgen in 2023 ...
    Endpoints · 3mo ago↗ source
  • The Godmother of Silicon Valley is helping launch an AI healthcare residency program
    Esther Wojcicki wants to help healthcare startup co-founders get along. That might seem simple, but co-founder disagreements are a big contributor to startups falling apart, she said. She’s got the…
    Endpoints · 3mo ago↗ source
  • Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud
    Novo Nordisk’s GLP-1 pill works in kids with diabetes: Type 2 diabetes patients aged 10 to 17 who took Rybelsus for about six months had a statistically significant 0.83% cut in their blood sugar l…
    Endpoints · 3mo ago↗ source
  • Amneal to buy a biosimilar company; Samsung Bio workers protest
    Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals to acquire biosimilar maker for $375M upfront: The generics and specialty drugmaker is s…
    Endpoints · 3mo ago↗ source
  • Endpoints wins Neal Awards for Trump and gene editing coverage, JPM event
    Endpoints News was recognized with three 2026 Neal Awards for its coverage of the drug industry's relationship with the Trump administration, a three-part series on the future of CRISPR gene editin…
    Endpoints · 3mo ago↗ source
  • Gravity Rail raises $2.75M from Redesign Health for AI patient communication
    A startup that helps healthcare providers handle calls, texts and follow-ups with patients using AI has raised seed funding, Endpoints News learned exclusively. Gravity Rail handles the process of…
    Endpoints · 4mo ago↗ source
  • Roche says its investigational breast cancer pill could outsell Herceptin
    Roche still has high sales hopes for its breast cancer pill giredestrant despite the drug’s failure in a first-line trial earlier this year. CEO Thomas Schinecker said Thursday that the drug could ...
    Endpoints · 4mo ago↗ source